How do you minimize the risk of cardiotoxicity in metastatic Her2 + breast cancer patients who are receiving trastuzumab and have a history of pre-existing cardiac disease?

Currently there are no proven strategies that are widely used to minimize the risk of cardiac toxicity in patients receiving Her2 therapy. Development of inexpensive, protective regimens with minimal side effects for patients at risk for cardiac dysfunction and the devlopment of models identifying w...